PharVision Advisers LLC Makes New $234,000 Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

PharVision Advisers LLC acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 9,675 shares of the company's stock, valued at approximately $234,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. SlateStone Wealth LLC grew its stake in shares of Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock valued at $257,000 after acquiring an additional 413 shares in the last quarter. Blume Capital Management Inc. grew its stake in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after acquiring an additional 600 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in shares of Hims & Hers Health by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock valued at $480,000 after acquiring an additional 628 shares in the last quarter. Harbour Investments Inc. grew its stake in shares of Hims & Hers Health by 18.8% in the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock valued at $127,000 after acquiring an additional 833 shares in the last quarter. Finally, LPL Financial LLC grew its stake in shares of Hims & Hers Health by 1.0% in the fourth quarter. LPL Financial LLC now owns 97,958 shares of the company's stock valued at $2,369,000 after acquiring an additional 980 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

Shares of HIMS traded down $0.15 during mid-day trading on Tuesday, reaching $54.68. The company had a trading volume of 11,245,646 shares, compared to its average volume of 30,286,330. The company's 50 day simple moving average is $38.37 and its 200 day simple moving average is $35.38. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98. The company has a market capitalization of $12.24 billion, a price-to-earnings ratio of 124.28 and a beta of 1.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. During the same period last year, the company posted $0.05 EPS. The firm's quarterly revenue was up 110.7% compared to the same quarter last year. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 47,534 shares of Hims & Hers Health stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $58.25, for a total transaction of $2,768,855.50. Following the sale, the chief executive officer now directly owns 285,194 shares in the company, valued at $16,612,550.50. This trade represents a 14.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Melissa Baird sold 33,333 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $25.78, for a total transaction of $859,324.74. Following the transaction, the chief operating officer now owns 805,083 shares of the company's stock, valued at approximately $20,755,039.74. The trade was a 3.98% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 601,633 shares of company stock worth $24,349,726 in the last ninety days. Company insiders own 13.71% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $61.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Morgan Stanley reduced their price objective on shares of Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Tuesday, April 29th. Leerink Partners increased their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $37.67.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.